SOHM, Inc. (SHMN)
| Previous Close | 0.0010 |
| Open | 0.0009 |
| Bid | 0.0000 x 0 |
| Ask | 0.0000 x 0 |
| Day's Range | 0.0009 - 0.0012 |
| 52 Week Range | 0.0005 - 0.0022 |
| Volume | |
| Avg. Volume | 1,645,786 |
| Market Cap | 1.921M |
| Beta (5Y Monthly) | 0.84 |
| PE Ratio (TTM) | N/A |
| EPS (TTM) | N/A |
| Earnings Date | N/A |
| Forward Dividend & Yield | N/A (N/A) |
| Ex-Dividend Date | N/A |
| 1y Target Est | N/A |
- GlobeNewswire
SOHM, Inc., Targets Revolutionary New ABBIE Genome Editing Kits for Q3, 2024
SOHM, Inc. Further Advances its Work in the Field of Genome Editing and ABBIE, a Retroviral Integrase with Linked Guided DNA Binding DomainCHINO HILLS, Calif., May 22, 2024 (GLOBE NEWSWIRE) -- via IBN -- SOHM, Inc. (OTC PINK: SHMN)– a leading generic pharmaceutical and upstart biotechnology company, is proud to announce its ongoing work on ABBIE (A Binding Based Integrase Enzyme), a revolutionary retroviral integrase with a linked dCas9 DNA binding domain. This groundbreaking technology has the
- GlobeNewswire
SOHM, Inc. and Coastar Therapeutics Sign MoU and Announce Collaboration to Revolutionize Genome Editing Using Red Blood Cell Membrane Derived Carriers
CHINO HILLS, Calif., April 01, 2024 (GLOBE NEWSWIRE) -- via IBN -- SOHM, Inc. (OTC PINK: SHMN), a pharmaceutical, nutraceutical and cosmeceutical company that manufactures and markets generic drugs covering numerous treatment categories, announces today the collaboration with Coastar Therapeutics, San Diego, California, a leading biotechnology company specializing in innovative drug delivery systems, and SOHM, a cutting-edge biopharmaceutical company focused on gene editing technologies, are exc
- GlobeNewswire
SOHM Files Provisional Patent on ABBIE’s ‘Smart Gene-Editing’ That Uses Latest Enzymes and Guide RNA to Resolve Off-Target Gene-Editing Limitations
CHINO HILLS, Calif., Jan. 09, 2024 (GLOBE NEWSWIRE) -- via IBN -- SOHM, Inc. (OTC PINK: SHMN) (the “Company”), a pharmaceutical, nutraceutical, cosmeceutical and biotech Company that manufactures and markets generic drugs covering numerous treatment categories, announces today the Company has filed a provisional patent application on its ABBIE “Smart Gene-Editing” platform that uses the latest enzymes and guide RNAs to resolve off-target gene-editing limitations. Gene-editing Market The gene-edi
